טוען...
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets
The treatment options in multiple myeloma (MM) has changed dramatically over the past decade with the development of novel agents such as proteasome inhibitors (PIs); bortezomib and immunomodulatory drugs (IMiDs); thalidomide, and lenalidomide which revealed high efficacy and improvement of overall...
שמור ב:
| הוצא לאור ב: | J Oncol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Hindawi
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6875016/ https://ncbi.nlm.nih.gov/pubmed/31781214 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/6084012 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|